3 Growth Stocks That Could Be 10-Baggers in 10 Years

Key Points

• The stocks listed here are all risky investments that have a lot of potential growth in the long run.

• These companies are all unprofitable and burning through a lot of cash.

• They are early leaders in their respective industries, however, and they could be appealing options for long-term investors.

• 10 stocks we like better than Joby Aviation ›

If you want to generate big investment returns in a relatively short time frame, you'll need to accept a higher level of risk and uncertainty along the way. One way to do that strategically is to invest modest amounts of money into several stocks that have lots of upside potential, but which are by no means sure things.

Three stocks that could be possible 10-baggers over the next decade are Joby Aviation (NYSE: JOBY), Rigetti Computing (NASDAQ: RGTI), and CRISPR Therapeutics (NASDAQ: CRSP). Here are the big risks they face, and the possible ways they could pay off for shareholders.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »

Joby Aviation

The air taxi industry is in its infancy, but there's growing optimism that it could help alleviate congestion in major cities and revolutionize how people travel. Joby Aviation is an early leader in the space, and in August, it completed a piloted flight of its electric vertical take-off and landing (eVTOL) vehicle between two public airports in California, marking a milestone for its business.

If the company obtains regulatory approval for its eVTOL -- and it looks on track to do so in the near future -- then it may begin offering air taxi services as soon as next year. The big question around the business centers around how much demand there will truly be for these services, and how long it may take for Joby to turn a profit, especially given that this will be a capital-intensive industry to operate in.

Analysts at Grand View Research project that the eVTOL market will grow at a compound annual rate of just under 55% through the end of the decade. If that pans out and Joby remains a leader in the industry, it could be well on its way to growing to 10 times its value.

Rigetti Computing

Quantum computing is another long-term play that could make for a compelling investment. These machines have the ability to solve certain unusual types of incredibly complex problems at lightning-fast speeds compared to classical computers that would take years or even centuries to solve. Rigetti recently released the Cepheus-1-36Q, which is the largest multi-chip quantum computer the industry has seen thus far.

CEO Subodh Kulkarni said he believes that the company could reach its key breakthrough within about four years:

"We believe we are still about 3 to 4 years away from getting to the 1,000-plus qubit, 99.9% fidelity with error correction and gate speeds of less than 50 nanoseconds, which is when we achieve quantum advantage."

The higher a machine's qubit count, the more complex the problems it can take on, while a high fidelity indicates a high level of accuracy. Right now, due to the extremely sensitive nature of qubits, accuracy and error reduction are two of the biggest issues companies in the quantum computing space are working to solve.

Rigetti is already generating revenue, but over the past four quarters, it has incurred losses totaling $169 million, and it has burned through $54 million on its day-to-day operating activities. There are still questions about how long it will be before quantum computers are commercially viable and can be reliably tasked to solve complex, real-world problems. And the big risk for investors with Rigetti is that it's unclear whether the tech company will be around in 10-plus years, or that it will remain a big player in the industry if it is.

Rigetti is making good progress, but it still has a lot to prove. If its quantum computers end up being the real deal, the stock could be well on its way to profitability and would be significantly more valuable than its current market cap of $9.6 billion.

CRISPR Therapeutics

CRISPR Therapeutics has the potential to play a big role in revolutionizing healthcare. It already has one approved gene editing therapy, Casgevy, which can treat sickle cell disease and transfusion-dependent beta thalassemia. It acts as a functional cure for both blood disorders, and it could be the first of many more treatments to come from the company.

One particularly exciting candidate therapy involving stem cells is CTX211, which CRISPR is researching as a possible treatment for type 1 diabetes. Meanwhile, a recent study from Japan also found that gene-editing could potentially be used to eliminate the extra chromosome that causes Down syndrome in people with the condition. There's promising potential in this area of healthcare, and CRISPR's stock can provide investors with some terrific exposure to these opportunities.

The company is still in the early stages of rolling out Casgevy with its partner, Vertex Pharmaceuticals, but in the meantime, it's also burning through cash. Over the past six months, it used up $168 million during the course of its day-to-day operating activities. The good news is that with cash and marketable securities totaling over $1.7 billion on its books, the company is well funded to support its current level of cash burn for multiple years.

With a market cap of just $5.8 billion today, this is a healthcare company that can become much more valuable in the next 10 years, but a lot will depend on its success and ability to roll out more gene editing therapies.

Should you invest $1,000 in Joby Aviation right now?

Before you buy stock in Joby Aviation, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Joby Aviation wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $631,456!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,147,755!*

Now, it’s worth noting Stock Advisor’s total average return is 1,063% — a market-crushing outperformance compared to 191% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of September 29, 2025

David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.